Dasher Neuroscience Completes Patient Recruitment for MSA Drug Trial
Dasher Neuroscience Holdings Inc. has completed patient recruitment for its global Phase II clinical trial of YA-101, an AI-developed drug candidate for multiple system atrophy (MSA).
Taipei – Dasher Neuroscience Holdings Inc. announced today that it has completed patient recruitment for its global Phase II clinical trial of YA-101, the company's lead drug candidate for the treatment of multiple system atrophy (MSA).
The Phase II study is designed to evaluate the efficacy and safety of YA-101 in patients with MSA. Dasher Neuroscience utilizes artificial intelligence in its drug discovery and development processes, focusing on the central nervous system.
MSA is a rare and progressive neurodegenerative disease with no cure. The company anticipates having primary data from the study within one year. YA-101 represents a significant development effort for Dasher Neuroscience in addressing unmet needs in neurological disorders.